论文部分内容阅读
紫杉醇是一种具有新细胞毒作用机理的抗微管药物。国立癌症研究所(NCI)的研究者首次用紫杉醇治疗复发性非霍奇金淋巴瘤(HNL),用紫杉醇96小时输注的疗效很低,并且只获部分有效(PRs)。本文报道紫杉醇3小时输注对复发性和顽固性NHL患者的疗效。 受试患者经组织学确诊为复发性或顽固性NHL。紫杉醇输注前4小时服地塞米松20mg。输注前30分钟以地塞米松20mg、苯海拉明50mg及西咪替丁300mg静注。紫杉醇(200mg/m~2)在门诊条件下行3小时静脉输注,每3周一次。紫杉醇剂量根据毒副作用而定,若中性粒细胞最低值>1000μl或血小板最低值>
Paclitaxel is an anti-microtubule drug with a new cytotoxic mechanism. Researchers at the National Cancer Institute (NCI) for the first time treated paclitaxel with relapsing non-Hodgkin’s lymphoma (HNL). The 96-hour infusion of paclitaxel was very ineffective and only partially effective (PRs). This article reported the efficacy of paclitaxel 3-hour infusion in patients with relapsed and refractory NHL. The patient was histologically diagnosed with recurrent or refractory NHL. Dexamethasone 20 mg was taken 4 hours before paclitaxel infusion. Dexamethasone 20 mg, diphenhydramine 50 mg, and cimetidine 300 mg were intravenously administered 30 minutes before infusion. Paclitaxel (200 mg/m~2) was intravenously infused 3 hours a day in outpatient conditions every 3 weeks. The dose of paclitaxel depends on toxic and side effects, if the neutrophil minimum value is >1000μl or the platelet minimum value>